BlackRock Institutional Trust’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlackRock Institutional Trust’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$19.8M	Buy	1,434,807 +159,346	+12%	+$2.56M	﹤0.01%	1971
2016 Q3	$23M	Buy	1,275,461 +181,063	+17%	+$2.91M	﹤0.01%	1789
2016 Q2	$15.7M	Sell	1,094,398 -12,810	-1%	-$174K	﹤0.01%	2002
2016 Q1	$13.2M	Buy	1,107,208 +6,770	+0.6%	+$71K	﹤0.01%	2090
2015 Q4	$14.6M	Buy	1,100,438 +17,225	+2%	+$212K	﹤0.01%	2073
2015 Q3	$11.6M	Sell	1,083,213 -107,418	-9%	-$1.17M	﹤0.01%	2189
2015 Q2	$9.59M	Buy	1,190,631 +29,178	+3%	+$214K	﹤0.01%	2434
2015 Q1	$7.68M	Buy	1,161,453 +67,140	+6%	+$458K	﹤0.01%	2554
2014 Q4	$6.97M	Buy	1,094,313 +43,666	+4%	+$352K	﹤0.01%	2563
2014 Q3	$10.4M	Buy	1,050,647 +709	+0.1%	+$7.57K	﹤0.01%	2315
2014 Q2	$11.8M	Buy	1,049,938 +1,825	+0.2%	+$19.6K	﹤0.01%	2324
2014 Q1	$12.7M	Buy	1,048,113 +21,320	+2%	+$272K	﹤0.01%	2263
2013 Q4	$12.9M	Sell	1,026,793 -64,221	-6%	-$1.02M	﹤0.01%	2245
2013 Q3	$18.2M	Sell	1,091,014 -45,870	-4%	-$769K	﹤0.01%	1934
2013 Q2	$17.3M	Buy	+1,136,884	New	+$17.3M	﹤0.01%	1917

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

BlackRock Institutional Trust's LXRX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Lexicon Pharmaceuticals (LXRX) stake by 12% in Q4 2016, buying an estimated $2.56M and bringing the position to 1,434,807 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1971.

BlackRock Institutional Trust first reported a position in LXRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $23M in Q3 2016. 146 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

BlackRock Institutional Trust held 1,434,807 shares of Lexicon Pharmaceuticals worth $19.8M as of Q4 2016.
BlackRock Institutional Trust bought 159,346 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $2.56M.
Lexicon Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1971 holding.
BlackRock Institutional Trust first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Lexicon Pharmaceuticals position peaked at $23M in Q3 2016.
146 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.